|
Male [n (%)]
|
51 (72.8)
|
|
Median age [years(IQR)*]
|
40 (37-46)
|
|
ARV* naïve before first line [n (%)]
|
15 (21.4)
|
|
PI naïve at switch [n (%)]
|
70 (100.0)
|
|
Initial first-line ARV treatment
| |
|
d4T/3TC/EFV [n (%)]
|
18 (26.1)
|
|
d4T/3TC/NVP [n (%)]
|
12 (17.1)
|
|
AZT/3TC/NVP [n (%)]
|
23 (33.3)
|
|
AZT/3TC/EFV [n (%)]
|
13 (18.8)
|
|
Other first lines [n (%)]
|
4 (5.8)
|
|
Follow-up time on first-line HAART* (months)
| |
|
Median (IQR)
|
26.6 (15.2-29.4)
|
|
Characteristics at switch
| |
|
CD4 T-cell counts (n)
|
70
|
|
Median nb cells/mm3 [n (IQR)]
|
106 (42-168)
|
|
Count <50 cells/mm3 [n (%)]
|
20 (28.6)
|
|
Median viral load (n = 65), [Log10 (IQR)]
|
4.7 (3.1-5.4)
|
|
Prescribed second-line ARV treatment
| |
|
ddI/3TC/LPV/r [n (%)]
|
46 (65.7)
|
|
TDF/3TC/LPV/r [n (%)]
|
5 (7.1)
|
|
TDF/ddI/LPV/r [n (%)]
|
7 (10.0)
|
|
AZT/ddI/LPV/r [n (%)]
|
6 (8.6)
|
|
AZT/3TC/LPV/r[n (%)]
|
2 (2.9)
|
|
Other second lines [n (%)]
|
4 (5.7)
|
|
Follow-up time on second-line HAART (months)
| |
|
Median (IQR)
|
37.3 (34.2-39.0)
|
